showed that 32.8 % of institutions are using the SGAC method for 75-100% of their patients and 64.1% are using field by field (FBF; perbeam) analysis for all of their patients. Even if these QA methods are widespread, there are few extensive comparison studies on the relevance of the different techniques. The goal of this research is to improve the understanding of the current QA methods by investigating the comparability of four different planar IMRT QA methods using the gamma passing rate 2 as the performance metric. Methods: IMRT verification plans were generated by the Varian Eclipse treatment planning system (TPS) for twelve heavily modulated head and neck (H&N) and twelve moderately modulated prostate treatment plans retrospectively selected for this study as summarized in Table I. The Varian TrueBEAM STX TM with high-definition MLC (HD120; 2.5 mm and 5 mm leaf width) was used to deliver the IMRT QA plans. For each of these patients, four different IMRT QA methods were performed: PGAC, SGAC, FBF, and PGAC using film (FPGAC). Sun Nuclear MapCHECK2 (2D diode array with detector spacing of 7.07 mm for SGAC, PGAC, and FBF) and GAFCHROMIC EBT2 film (0.34 mm/pixel for FPGAC) respectively sandwiched with 10 cm thick water equivalent phantom were used for the IMRT plan verification. For FPGAC, an ionization chamber (PTW TN31010) measurement was also performed at the isocenter or a point of high dose and low gradient. The film was scanned using the Epson Expression 10,000 XL flat bed scanner and was analyzed using the same Sun Nuclear "Patient" software for the MapCHECK2 QA. Considering MapCHECK2 has 1% inherent dosimetric uncertainty reported by the vendor, the gamma criteria (MapCHECK2/Film) of 1% (dose difference)-1mm (DTA)/2%-1mm (G1), 2%-2mm/3%-2mm (G2), and 3%-3mm/4%-3mm (G3) were used to determine the percentage of points passed for each verification plan. FPGAC has more comparison points for the QA by a factor of about 100 than the MapCHECK2-based methods. Absolute dose comparison (using absolute dose data; not normalized to a selected dose point such as a point of the maximum dose) with 10% threshold (used to exclude low dose points from appearing to fail) was adopted for the QA analysis. For the FBF analysis, the overall passing rate for each plan was the weighted average (the weighting based on the number of MUs for the each field) of the passing rates for the individual fields. Statistical analysis (Student's t-test) was employed to examine the agreement between two different methods and modulations. Results: The average passing rates of the gamma test were shown in Table II . They (H&N/Prostate) were 98.9/99.7% (PGAC), 99.6/100.0% (SGAC), 99.5/100.0% (FBF), and 92.0/95.8% (FPGAC) with the G3 criteria. FPGAC showed systematically lower passing rates than the MapCHECK2 methods with all gamma criteria. For FPGAC, the average dose difference between planning (P) and the ionization chamber measurement (M) was -0.15±1.05% ((M-P)/P×100) for all 24 plans. Three MapCHECK2 QAs had statistically comparable passing rates for all comparisons (p-value>0.05) as shown in Table III . The three MapCHECK2 QA methods did not show significant difference in the passing rate between H&N and Prostate plans. Especially, in some cases, the moderately modulated Prostate plans had lower passing rate than the highly modulated H&N plans using PGAC and FBF. However, FPGAC showed statistically different passing rate between H&N and Prostate plans with all gamma criteria (p-values of 0.037 (G1), 0.012 (G2), and 0.016 (G3)) as shown in Table IV . Conclusion: Three IMRT QA methods using MapCHECK2 are found to be comparably used for routine IMRT QA for both H&N and Prostate plans. This is against the belief that PGAC might be more effective patient specific IMRT QA than FBF or SGAC.
3 FPGAC showed significantly different passing rate based on the degree of plan modulation. These findings imply that the gamma passing rate heavily depends on the spatial resolution of detectors for the planar QA. Clinically acceptable  passing rate based on the detector resolution should be further studied since the intrinsic limitations of the gamma test were known. 25, 656-661 (1998) . 3 J. J. Kruse, "On the insensitivity of single field planar dosimetry to IMRT inaccuracies," Med Phys 37, 2516 -2524 (2010 . 4 H Zhen, et al, "Moving from gamma passing rates to patient DVH-based QA metrics in pretreatment dose QA," Med Phys 38, 5477-5489 (2011) . 
